Kardigan
PublicKardigan is now publicly traded
The data on this page reflects Kardigan's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Oct 14, 2025
Total Funding Raised
$554M
Company Overview
Kardigan is a biopharmaceutical company that develops targeted cardiovascular medicines by integrating translational biology, biomarker-driven clinical trials, and AI-driven real-world data.
AI Layer
Infrastructure
Keywords
Kardigan Comparables
Compare Kardigan with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cardurion Pharmaceuticals | 83% | |
| Tenaya Therapeutics | 80% | |
| Cytokinetics, Incorporated | 77% |
For institutional investors. Book with your work email.
Kardigan Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 14, 2025 | ||||
| Series A | Jan 10, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kardigan Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Perceptive Advisors | Series A |
| HRTG Partners | Series B, Series A |
| Fidelity Management & Research Company | Series B |
| ARCH Venture Partners | Series B, Series A |
| T. Rowe Price | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 30, 2026
In an announcement from California and New Jersey, Kardigan appoints Kristin Reinke to its Board of Directors, where she serves as chair of the Audit Committee, effective Sep 29th '26.
For institutional investors. Book with your work email.
Kardigan Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.